专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20080220181A1 Method of loading a nanotube structure and loaded nanotube structure 审中-公开
标题翻译：加载纳米管结构和负载纳米管结构的方法
公开(公告)号：US20080220181A1
公开(公告)日：2008-09-11
申请号：US11895370
申请日：2007-08-24
申请人： Nadarajan S. Babu , Elisabeth S. Papazoglou , Peter D. Katsikis
发明人： Nadarajan S. Babu , Elisabeth S. Papazoglou , Peter D. Katsikis
IPC分类号： B05D7/22 , B05D3/06
CPC分类号： B05D7/22 , B05D3/06 , B82Y30/00 , B82Y40/00 , C01B32/168 , C01B32/174
摘要： Nanotubes loaded with materials, such as active species, and methods to load materials into nanotubes are disclosed. The method includes flowing a medium containing the material to be loaded through the interior volume of the nanotube, wherein it is retained, optionally by a crosslinking or polymerization reaction. Flowing the medium occurs under different conditions and processes, including centrifuging and size exclusion methods.
摘要翻译：公开了装载材料（例如活性物质）的纳米管和将材料负载到纳米管中的方法。该方法包括使包含要加载的材料的介质流动通过纳米管的内部容积，其中其被保持，任选地通过交联或聚合反应。在不同的条件和过程下，介质的流动，包括离心和尺寸排除方法。

22. 发明申请

US20130156761A1 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same 有权
标题翻译：用于抑制癌症转移的化合物和使用其的方法
公开(公告)号：US20130156761A1
公开(公告)日：2013-06-20
申请号：US13776220
申请日：2013-02-25
申请人： Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine , Alliance Discovery, Inc.
发明人： Alessandro Fatatis , Joseph M. Salvino , Olimpla Meucci , Whitney L. Jamieson
IPC分类号： A61K39/395 , A61K31/7088 , A61K31/451 , A61K31/453 , C07K16/28 , C07D403/04
CPC分类号： C07D487/04 , A61K31/451 , A61K31/453 , A61K31/7088 , A61K39/3955 , C07D403/04 , C07K16/28
摘要： The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.
摘要翻译：本发明包括可用于预防或治疗患有癌症的受试者的转移的组合物。本发明还包括预防或治疗患有癌症的受试者的转移的方法，其中所述方法包括向有需要的受试者施用有效量的药物制剂，其包含至少一种药学上可接受的载体和至少一种CX3CR1或fractalkine 拮抗剂。

23. 发明申请

US20110256538A1 EPIGENOMIC DNA MODIFICATIONS FOR TISSUE TYPING, EARLY CANCER DETECTION, AND DISEASE MANAGEMENT 审中-公开
标题翻译：用于组织类型，早期癌症检测和疾病管理的原始DNA修饰
公开(公告)号：US20110256538A1
公开(公告)日：2011-10-20
申请号：US13087029
申请日：2011-04-14
申请人： Ying-Hsiu Su , Surbhi Jain
发明人： Ying-Hsiu Su , Surbhi Jain
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/154 , C12Q2600/156 , C12Q2600/16
摘要： Provided herein is a suitable method for detecting the presence or absence of a cancer in an individual, by determining the level of methylation of the sense strand of a selected regulatory region of a tumor suppressor gene. Also provided herein is a method of detecting the presence or absence a cancer in an individual by determining if there is an apparent 100% methylation by assay of the CpG sites in the anti-sense strand of a selected regulatory region of a tumor suppressor gene. Also provided herein is a method of tissue typing by determining the level of methylation of the anti-sense strand of a selected regulatory region of a tumor suppressor gene indicating an enhanced likelihood that a tissue is liver.
摘要翻译：本文提供了通过确定肿瘤抑制基因选定的调节区域的有义链的甲基化水平来检测个体中癌症存在或不存在的合适方法。本文还提供了通过测定肿瘤抑制基因的选定调节区的反义链中CpG位点是否存在明显的100％甲基化来检测个体中癌症存在或不存在的方法。本文还提供了通过确定肿瘤抑制基因的所选调节区的反义链的甲基化水平来指示组织为肝脏的可能性增加的组织分型方法。

24. 发明申请

US20100094149A1 Noninvasive Ultrasound Cardiac Pacemaker and Defibrillator 审中-公开
标题翻译：无创超声心脏起搏器和除颤器
公开(公告)号：US20100094149A1
公开(公告)日：2010-04-15
申请号：US12558294
申请日：2009-09-11
申请人： Andrew R. Kohut , Peter B. Kurnik , Peter A. Lewin , Christopher Vecchio
发明人： Andrew R. Kohut , Peter B. Kurnik , Peter A. Lewin , Christopher Vecchio
IPC分类号： A61B5/0472 , A61N7/00
CPC分类号： A61B5/0472 , A61N7/00 , A61N2007/0026 , A61N2007/0078
摘要： A device for providing extracorporeal cardiac pacing. The device includes an ultrasound transducer mountable to the external thorax of a patient and an ultrasound generator for transmitting ultrasound pulses to the ultrasound transducer. The heart rate of a patient is monitored by the device. A controller evaluates the heartbeat as compared with threshold criteria for stimulation of the heart and causes the ultrasound generator to deliver ultrasound pulses to the ultrasound transducer at a prescribed intensity, frequency, and pulse duration.
摘要翻译：用于提供体外心脏起搏的装置。该装置包括可安装到患者的外部胸部的超声波换能器和用于将超声波脉冲发射到超声换能器的超声波发生器。患者的心率由设备监测。与心脏刺激的阈值标准相比，控制器对心跳进行评估，并使超声波发生器以规定的强度，频率和脉冲持续时间将超声波脉冲传送到超声换能器。

25. 发明申请

US20090017055A1 PLASMODIUM LIVER STAGE ANTIGENS 有权
标题翻译： PLASMODIUM肝脏阶段抗原
公开(公告)号：US20090017055A1
公开(公告)日：2009-01-15
申请号：US12088065
申请日：2006-09-29
申请人： Patrick Duffy , Stefan H. I. Kappe , Urszula Krzych , Donald G. Heppner, JR. , Lawrence W. Bergman , Vladislav A. Malkov , Alice Tarun , Jason W. Wendler , Igor Bacik
发明人： Patrick Duffy , Stefan H. I. Kappe , Urszula Krzych , Donald G. Heppner, JR. , Lawrence W. Bergman , Vladislav A. Malkov , Alice Tarun , Jason W. Wendler , Igor Bacik
IPC分类号： A61K39/015 , C07K14/445 , C07H21/00 , A61P33/06
CPC分类号： C07K14/445 , A61K39/00 , Y02A50/412
摘要： The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.
摘要翻译：本发明提供了分离的肝阶段疟原虫多肽，其包含选自SEQ ID NO：1-48的氨基酸序列及其免疫原性衍生物。本发明还提供编码本发明的肝阶段疟原虫多肽的分离的核酸分子，包含本发明的一种或多种肝阶段疟原虫多肽的组合物，诱导针对肝阶段的疟原虫多肽的免疫应答的方法，以及治疗和诊断方法肝阶段疟疾。

26. 发明申请

US20080319247A1 Method of local therapy using magnetizable thermoplastic implant 审中-公开
标题翻译：使用可磁化热塑性植入物的局部治疗方法
公开(公告)号：US20080319247A1
公开(公告)日：2008-12-25
申请号：US12214647
申请日：2008-06-20
申请人： Zachary Graham Forbes , Steven Michael Kurtz
发明人： Zachary Graham Forbes , Steven Michael Kurtz
IPC分类号： A61N2/00 , A61F2/02 , A61H1/00 , A61B19/00
CPC分类号： A61N2/06 , A61N2/002 , A61N2/02
摘要： A method for local therapies using heat generating implants comprising magnetic or magnetizable features or objects distributed in a solidified moldable matrix to treat bone infection or loosening of implants by the mechanism of hyperthermia or thermoablation.
摘要翻译：一种使用发热植入物的局部疗法的方法，其包括分布在固化的可模制基质中的磁性或可磁化特征或物体，以通过热疗或热消融机制来治疗骨骼感染或松动植入物。

27. 发明申请

US20080188645A1 Synthesis of Nitrodibenzylfuran Chromophore For Photodeprotection of Organic Molecules 有权
标题翻译：用于有机分子光保护的硝基二苄基衍生物的合成
公开(公告)号：US20080188645A1
公开(公告)日：2008-08-07
申请号：US11911250
申请日：2006-04-12
申请人： Graham Ellis-Davies , Atsuya Momotake
发明人： Graham Ellis-Davies , Atsuya Momotake
IPC分类号： C07D307/91 , C07D209/82 , C07D491/048 , C07H15/00 , C07F9/06
CPC分类号： C07H19/16 , A61K41/0042 , C07D307/91 , C07D491/04 , C07F9/65517
摘要： Inventors have developed a chromophore (nitrodibenzylfuranyl, or NBDF) for ultra efficient uncaging of a caged substrate (e.g., an organic molecule such as, for example, an amino acid, a biological molecules, such as, for example, second messengers inside cells). Photolysis of a NBDF derivative of EGTA (i.e. caged calcium) is about 50 times more efficient than others calcium cages (the quantum yield of photolysis is 0.6 and the extinction coefficient is 18,400. NDBF-EGTA has a 2-photon cross section of about 0.3-0.6 GM).
摘要翻译：发明人已经开发了用于超滤效能笼罩底物（例如，有机分子例如氨基酸，生物分子，例如细胞内的第二信使）的发色团（硝基二苄基呋喃基或NBDF）。 EGTA的NBDF衍生物（即笼养钙）的光解比其他钙笼蛋白的效价高约50倍（光解的量子产率为0.6，消光系数为18,400），NDBF-EGTA的双光子截面约为0.3 -0.6 GM）。

28. 发明申请

US20140308657A1 SERINE PROTEASE INHIBITOR KAZAL ANTIBODIES 审中-公开
标题翻译：丝氨酸蛋白酶抑制剂KAZAL抗体
公开(公告)号：US20140308657A1
公开(公告)日：2014-10-16
申请号：US13991943
申请日：2011-12-07
申请人： Xuanyong Lu , Timothy M. Block
发明人： Xuanyong Lu , Timothy M. Block
IPC分类号： G01N33/569 , C07K16/38
CPC分类号： G01N33/56983 , C07K16/38 , C07K2317/34 , C12Q1/37 , G01N33/57438 , G01N33/5761 , G01N33/5767 , G01N2800/50
摘要： This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis). Also provided is an anti-SPIK antibody specific for an epitope comprising the first nine amino acids of intact SPIK. Further, a diagnostic kit is provided comprising at least one antibody specific for an epitope comprising the first nine amino acids of intact SPIK to diagnose patients exhibiting disease symptoms or at risk for developing a disease, wherein the disease is HBV infection, HCV infection, hepatitis, cancer or hepatic cancer.
摘要翻译：本发明描述了癌症的相关病因和新型抗癌治疗策略，基于以下发现：称为丝氨酸蛋白酶抑制剂（SPIK / SPINK / PSTI）的蛋白质被乙型和丙型肝炎病毒感染上调，从而抑制细胞凋亡。因此，本发明提供了SPIK抑制剂和/或抑制细胞中SPIK过度表达的技术。抑制剂包括：1）可抑制SPIK转录物，蛋白质活性和基因表达的化合物，2）SPIK siRNA（SPIK的RNAi基因沉默或dsRNA，3）DNA反义和抗SPIK抗体。此外，本发明提供了使用该抑制剂作为抗癌剂来重新制备癌细胞凋亡（如丝氨酸蛋白酶依赖性细胞凋亡）的方法。还提供了对包含完整SPIK的前9个氨基酸的表位特异的抗SPIK抗体。此外，提供了诊断试剂盒，其包含至少一种特异于包含完整SPIK的前九个氨基酸的表位的抗体，以诊断表现出疾病症状或处于发展疾病的风险的患者，其中所述疾病是HBV感染，HCV感染，肝炎，癌症或肝癌。

29. 发明申请

US20140228380A1 Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease 有权
公开(公告)号：US20140228380A1
公开(公告)日：2014-08-14
申请号：US13957861
申请日：2013-08-02
申请人： University of Medicine and Dentistry New Jersey Medical School , Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
发明人： Sandhya Kortagere , Eldo V. Kuzhikandahil
IPC分类号： C07D471/04 , C07D235/16 , C07C211/29 , C07D209/14 , C07C215/08 , C07C215/54
CPC分类号： A61K31/137 , A61K31/198 , A61K31/4045 , A61K31/4184 , A61K31/428 , A61K31/473 , A61K31/48 , A61K31/506 , A61K31/519 , A61K31/5513 , A61K45/06 , C07C211/29 , C07C215/08 , C07C215/54 , C07C217/62 , C07D209/14 , C07D235/16 , C07D471/04 , A61K2300/00
摘要： The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.

30. 发明申请

US20140120136A1 MIR-155 ENHANCEMENT OF CD8+ T CELL IMMUNITY 审中-公开
标题翻译： MIR-155增强CD8 + T细胞免疫
公开(公告)号：US20140120136A1
公开(公告)日：2014-05-01
申请号：US14051895
申请日：2013-10-11
申请人： The Babraham Institute , Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
发明人： Peter D. Katsikis , Donald T. Gracias , Martin Turner
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , A61K35/17 , C12N5/0636 , C12N2310/141 , C12N2501/65
摘要： The present invention provides novel methods of enhancing CD8+ T cell mediated immunity (also referred to as “CD8+ T cell immunity”) in a patient having a diseased state. In particular, the present invention provides for the enhanced expression of miR-155 in a population of patient specific T cells through the introduction of a nucleic acid molecule encoding a miR-155 transcript or a nucleic acid molecule encoding a chimeric antigen receptor and a miR-155 transcript into those cells, followed by the reintroduction of the T cells into the patient. The present invention also provides methods of enhancing the expansion of these T cells relative to control cells. Increased expansion of CD8+ T cells following enhanced miR-155 expression is directly related to enhanced CD8+ T cell immunity. The present invention further provides methods of enhancing anti-cancer immunity in a patient through the increased expression of miR-155 in patient specific T cells.
摘要翻译：本发明提供了具有疾病状态的患者中增强CD8 + T细胞介导的免疫（也称为“CD8 + T细胞免疫”）的新方法。特别地，本发明通过引入编码miR-155转录物的核酸分子或编码嵌合抗原受体和miR的核酸分子来提供miR-155在患者特异性T细胞群体中的增强表达 -155转录到这些细胞中，随后将T细胞重新引入患者体内。本发明还提供了相对于对照细胞增强这些T细胞的扩增的方法。增强的miR-155表达后CD8 + T细胞的增加与增强的CD8 + T细胞免疫直接相关。本发明还提供了通过增加miR-155在患者特异性T细胞中的表达来增强患者抗癌免疫的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式